IL6R and rheumatoid arthritis: Interleukin-6 receptor inhibition with Tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying anti-rheumatic drugs: the Tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study